A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban

Trial Profile

A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Ifetroban (Primary)
  • Indications Embolism and thrombosis; Hepatorenal syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Cumberland Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 03 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by Cumberland media release.
    • 03 Nov 2015 According to Cumberland media release, enrolment in the Type I cohort is now complete and top-line results of this cohort is expected later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top